Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

RELION NOVOLIN N 100 UNIT/ML

Human Insulin
$13.4749per ML
OTC

Strength

100 [iU]/mL

Manufacturer

Novo Nordisk

NDC

00169183402

Classification

Brand

Dosage Form

INJECTION, SUSPENSION

Route

SUBCUTANEOUS

Last Updated

2/21/2018

Active Ingredients

INSULIN HUMAN

Approval Type

Biologic (BLA)

FDA Application

BLA019959

On Market Since

7/1/1991

Pharmacological Classes

Insulin
Insulin

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

0.0%

3Y

0.0%

5Y

0.0%

All

+67.1%

Generic Alternatives

Save up to 66%

1 alternative • Same active ingredient

NOVOLIN R 100 UNIT/ML VIAL
Brand
00169183311•Novo Nordisk
$4.6226
Save 66%

Related Drugs

Same classification

HUMULIN 70-30 VIAL
Brand
00002871501•Eli Lilly and Company
$4.2626
per ML
HUMULIN R 100 UNIT/ML VIAL
Brand
00002821501•Eli Lilly and Company
$4.2660
per ML
HUMULIN N 100 UNIT/ML VIAL
Brand
00002831501•Eli Lilly and Company
$4.2686
per ML
AFREZZA (REGULAR INSULIN) 4 UNIT CARTRIDGE
Brand
47918087490•Mannkind Corporation
$5.1957
per EA
LANTUS 100 UNIT/ML VIAL
Brand
00088222033•Sanofi-Aventis U.S. LLC
$6.1584
per ML
LANTUS SOLOSTAR 100 UNIT/ML
Brand
00088221905•Sanofi-Aventis U.S. LLC
$6.1661
per ML
NOVOLOG MIX 70-30 VIAL
Brand
00169368512•Novo Nordisk
$6.9325
per ML
FIASP 100 UNIT/ML VIAL
Brand
00169320111•Novo Nordisk
$6.9327
per ML
NOVOLOG 100 UNIT/ML VIAL
Brand
00169750111•Novo Nordisk
$6.9387
per ML
NOVOLOG PENFILL 100 UNIT/ML
Brand
00169330312•Novo Nordisk
$8.5732
per ML

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy